We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide provides market update
12 Jul 2022 - The EBITDA margin for the first half of 2022 is expected to be around 20% of revenue. Media Release – ad hoc announcement pursuant to Art. […]
Read morePolyPeptide achieves strong profitable growth in 2021
15 Mar 2022 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the financial year 2021: Revenue growth of […]
Read morePolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen
1 Dec 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Neil Thompson as Director Global Sales and Marketing and member […]
Read moreResults of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG
10 Nov 2021 - PolyPeptide Group AG (“PolyPeptide”) has been informed that Draupnir Holding B.V. (“Draupnir”), which held 60.0% of PolyPeptide’s share capital as of close of trading on SIX […]
Read morePolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends
17 Aug 2021 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the first half of 2021: – Revenue […]
Read morePolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee
25 Jun 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Christina Del Vecchio as General Counsel and member of the […]
Read morePolyPeptide Group announces the exercise of the full over-allotment option
5 May 2021 - PolyPeptide Group AG ("PolyPeptide" or "the Group"), a global leader in peptide development and manufacturing, today announced that the Joint Global Coordinators have exercised in full the over-allotment option granted in connection with its Initial Public Offering (the "IPO") at the offer price of CHF 64 per share.
Read more